AI-Designed Insilico Drug Flashes Signs of Efficacy in Lung …
WEB18 hours ago · Insilico Medicine’s idiopathic pulmonary fibrosis drug led to dose-dependent improvement in lung function in a mid-stage study. Meanwhile, Pliant Therapeutics and PureTech Health are also making ...
Insilico Medicine Reports Positive Phase IIa Results for ISM001 …
WEB4 days ago · News provided by. Insilico Medicine Sep 18, 2024, 09:30 ET. Share this article. Share to X. Share this article. Share to X. ISM001-055 is a novel drug designed in-house using generative AI to ...
Press Releases | Insilico Medicine
WEBJul 25, 2024 · Insilico Medicine announces AI drug discovery milestone achievement in pharma collaboration. 12 December 2023. In 7 months, online Target ID course from AI drug discovery company Insilico Medicine surpasses 2,500 users. 11 December 2023.
Insilico Medicine Reports Positive Phase IIa Results for ISM001 …
WEB4 days ago · Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results from its Phase IIa clinical trial evaluating ISM001-055. ISM001-055 is a ...
Insilico Medicine Reports Positive Phase IIa Results for
WEB4 days ago · PR Newswire Insilico Medicine Reports Positive Phase IIa Results for ISM001-055, a Novel First-in-Class Drug Treatment for Idiopathic Pulmonary Fibrosis (IPF) Designed Using Generative AI
Insilico Medicine Reports Positive Phase IIa Results for ... - BioSpace
WEB4 days ago · While preliminary, this clinical data is certainly encouraging, and provides the clinical validation of AI-powered drug R&D for both novel target and novel molecule,” said Feng Ren, PhD, co-CEO and CSO of Insilico Medicine. " This is a significant milestone for Insilico Medicine and the AI driven drug discovery Industry.
First Generative AI Drug Begins Phase II Trials with ... - Insilico
WEBJul 1, 2023 · Insilico Medicine has achieved a new milestone in artificial intelligence drug discovery – bringing the first drug discovered and designed by generative AI into Phase II clinical trials with patients.
Insilico Medicine announces positive topline results of the
WEBNew York, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine (“Insilico”), a clinical stage artificial intelligence (AI)-driven drug R&D company, today announces positive topline results of...
First Drug Discovered and Designed with Generative AI Enters …
WEBJun 28, 2023 · Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems.
Insilico Medicine reports data from Phase IIa IPF treatment trial
WEB3 days ago · Insilico Medicine has announced positive preliminary results from its Phase IIa clinical trial of ISM001-055, a small molecule drug designed using generative AI, to treat idiopathic pulmonary fibrosis (IPF). The randomised, double-blind, placebo-controlled trial was conducted across 21 sites in China, enrolling 71 patients with IPF.
Skip to content